6/28/2019  12:00:00 AM Chg. - Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
59.000EUR - 0
Turnover: 0.000
-Bid Size: - -Ask Size: - 3.35 bill.EUR - -

Business description

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world’s largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech’s investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.
 

Management board & Supervisory board

CEO
Dr. Daniel Koller
Management board
Dallas Webb, Dr. Christian Koch, Dr. Maurizio Bernasconi, Dr. Samuel Croset, Dr. Stephen Taubenfeld, Felicia Flanigan
Supervisory board
Dr. Erich Hunziker, Dr. Clive Meanwell, Dr. Thomas von Planta, Prof. Dr. Mads Krogsgaard Thomsen
 

Company data

Name: BB Biotech AG
Address: Schwertstraße 6,CH-8200 Schaffhausen/Schweiz
Phone: +41-52-624-0845
Fax: -
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.com
Industry: Financial
Sector: Specialty Finance
Sub sector: Diversified Financial
End of financial year: 12/31
Free Float: 96.47%
IPO date: 12/10/1997

Investor relations

Name: Dr. Silvia Siegfried-Schanz
IR phone: +41-44-267-7266
IR Fax: -
IR e-mail: ssc@bellevue.ch

Company calendar

CW 3 | 1/20/2023 4th Quarter/Annual Report
CW 7 | 2/17/2023 4th Quarter/Annual Report
CW 12 | 3/23/2023 General Shareholder Meeting
 

Main Shareholders

Freefloat
 
96.47%
Lazard Asset Management LLC, New York, USA
 
3.53%